Note: Descriptions are shown in the official language in which they were submitted.
CA 03172795 2022-08-23
NOVEL USE OF MULTI-KINASE INHIBITOR
TECHNICAL FIELD
[0001] The present invention belongs to the technical field of
medicines, and particularly
relates to a multi-kinase inhibitor compound or a pharmaceutically acceptable
salt, a
stereoisomer and a crystal form thereof for use in the treatment of biliary
tract cancer, a
pharmaceutical composition comprising the multi-kinase inhibitor compound or a
pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof, a
method for
treating biliary tract cancer by using the multi-kinase inhibitor compound or
a pharmaceutically
acceptable salt, a stereoisomer and a crystal form thereof, use of the multi-
kinase inhibitor
compound or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof in
the treatment of biliary tract cancer, and use of the multi-kinase inhibitor
compound or a
pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof in
the preparation of
a medicament for treating biliary tract cancer.
BACKGROUND
[0002] Biliary tract cancer (BTC) is a malignant tumor derived from biliary
epithelial
cells, and is relatively rare clinically and has a low incidence rate, but in
recent years, it tends to
increase gradually. As its early clinical symptoms lack specificity, most
diagnosed patients are
at the advanced stage. It can be classified into cholangiocarcinoma (CCA) and
gallbladder
carcinoma (GBC) according to anatomical location.
[0003] Cholangiocarcinoma is a highly heterogeneous malignant tumor that
develops in
the biliary tract, accounting for approximately 3% of all digestive system
tumors.
Cholangiocarcinoma can be classified into three types according to the
anatomical site of a
lesion, including intrahepatic cholangiocarcinoma (iCC), perihilar
cholangiocarcinoma (pCC),
and distal cholangiocarcinoma (dCC). Intrahepatic cholangiocarcinoma is
located in the liver
parenchyma and accounts for approximately 10%-20% of cholangiocarcinoma, and
perihilar
cholangiocarcinoma and distal cholangiocarcinoma are both extrahepatic
cholangiocarcinoma
and accounts for approximately 80% of cholangiocarcinoma (Rizvi, S., & Gores,
G.J. (2013),
1
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma.
Gastroenterology, 145(6),
1215-1229). The prognosis of cholangiocarcinoma is poor, wherein patients have
no obvious
clinical symptoms in the early stage, and metastasis usually occurs when
diagnosis is
confirmed. Because of the significant resistance of cholangiocarcinoma to
chemotherapy,
chemotherapy is often used in palliative treatments, the generally effective
treatment being
surgical resection and/or liver transplantation. Surgery is the primary
treatment for resectable
cholangiocarcinoma, and the post-operative survival rate depends mainly on
tumor margin
negativity, no vascular infiltration and lymphatic metastasis, and sufficient
residual liver to be
functional. Since most diagnosed patients are at the advanced stage,
recurrence is common,
with a recurrence rate of approximately 49%-64% within 2-3 years after
surgical resection.
The survival rate of patients after surgical resection for five years is also
poor, with the survival
rate of intrahepatic cholangiocarcinoma being 22%-44%, the survival rate of
perihilar
cholangiocarcinoma being 11%-41%, and the survival rate of distal
cholangiocarcinoma being
27%-37%. Only less than 1/3 of patients have the opportunity to receive
surgical resection due
to local tumor infiltration, peritoneal or distant metastasis, lack of biliary
reconstruction
protocols, and prediction of insufficient residual liver after surgery. For
cholangiocarcinoma
patients who are unable to undergo surgical resection, another treatment
option is liver
transplantation. However, liver transplantation has very strict selection
criteria and limited
availability for patients, and even among patients who can receive liver
transplantation,
prognosis is still poor, the recurrence rate is high, and the survival rate is
only 10%-25%.
Currently, the preferred choice for treatment of patients with unresectable or
metastatic tumors
includes: 1) clinical trials; 2) fluorouracil-based or gemcitabine-based
chemotherapy; or 3)
optimal supportive treatment.
[0004] The incidence rate and mortality rate of cholangiocarcinoma is
on an increasing
trend year by year. Current research conditions suggest that the development
and treatment of
cholangiocarcinoma may be associated with multiple targets.
[0005] Fibroblast growth factor receptor (FGFR) can regulate the
survival and
proliferation of cells, and a plurality of researches suggest that FGFR
aberration is a potential
therapeutic target of a plurality of tumors. FGFR2 fusion is one of the
important inducing
2
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
factors of cholangiocarcinoma, and the gene is commonly found in intrahepatic
cholangiocarcinoma and accounts for approximately 15% of intrahepatic
cholangiocarcinoma.
In addition to FGFR fusion aberration, cholangiocarcinoma has also been found
to be drug
resistant to a range of FGFR aberrations, such as FGFR2 N549H, FGFR2 V564F,
FGFR3
K650E, and FGFR3 R248C (Shiao MS, Chiablaem K, Charoensawan V, et al.
Emergence of
Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the
Solutions
for a Rare Cancer Type. Frontiers in Genetics. 2018;9:309).
[0006] The Janus kinase/signal transducer and activator of
transcription (JAK/STAT)
pathway may be involved in cancer cell proliferation and regulation of the
tumor
microenvironment via IL6 (Labib PL, Goodchild G, Pereira SP. Molecular
Pathogenesis of
Cholangiocarcinoma. BMC Cancer. 2019;19(1):185). Constitutive phosphorylation
of STAT3
has been reported in a panel of 7 different genetic profiles of human
cholangiocarcinoma cell
lines, demonstrating that the negative feedback loop of the IL-6/JAK/STAT3
pathway is
epigenetically silenced in cholangiocarcinoma cells, resulting in sustained
signaling (Isomoto
H, Mott JL, Kobayashi S, et al. Sustained IL-6/STAT-3 signaling in
cholangiocarcinoma cells
due to SOCS-3 epigenetic silencing. Gastroenterology. 2007;132(1):384-396).
[0007] The expression of Aurora A kinase (Aurora A) is also likely to
be up-regulated in
cholangiocarcinoma and is associated with poor progression-free survival and
overall survival
(Ding X, Huang T, Alm KS, et al. 5u1459 ¨ Aurora Kinase A Sustains
Cholangiocarcinoma
Proliferation and Represents a New Therapeutic Target. Gastroenterology.
2018 ;154(6): S-1153). W02018108079A1 discloses a class of multi -kinase
inhibitor
compounds capable of inhibiting, modulating and/or regulating the activity of
one or more
protein kinases such as Aurora kinase and VEGFR kinase, thereby having an anti-
tumor effect.
[0008] In summary, the optimal adjuvant therapy strategy after
cholangiocarcinoma
surgery is uncertain, and the clinical outcome in support of standard adjuvant
therapy protocols
is very limited. Currently, targeted inhibitors for cholangiocarcinoma are
researched clinically,
but there are still many cholangiocarcinoma patients who do not carry FGFR
aberrations and
also urgently need effective targeted therapy, so that huge unmet needs exist
clinically for
cholangiocarcinoma with FGFR aberration, non-FGFR aberration and wild type
FGFR, and the
3
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
research and development of effective targeted formulations for
cholangiocarcinoma are
urgently needed clinically.
SUMMARY
[0009] 1. Brief Description of the Invention
[0010] The present invention researches novel use of a multi-kinase
inhibitor compound
of the following general formula (I) or a pharmaceutically acceptable salt, a
stereoisomer and a
crystal form thereof in the field of cancers. Researches find that the multi-
kinase inhibitor
compound of general formula (I) or the pharmaceutically acceptable salt, the
stereoisomer and
the crystal form thereof has a treatment effect on biliary tract cancer, and
particularly has a
remarkable treatment effect on cholangiocarcinoma.
[0011] Therefore, the present invention aims to provide novel use of a
multi-kinase
inhibitor compound of general formula (I) or a pharmaceutically acceptable
salt, a stereoisomer
and a crystal form thereof in the treatment of biliary tract cancer.
[0012] Therefore, in a first aspect of the present invention, provided
is use of a compound
of general formula (I) or a pharmaceutically acceptable salt, a stereoisomer
and a crystal form
thereof in the preparation of a medicament for treating biliary tract cancer:
H
,N
)\ r
FIN N
i
\ Ar
P,
W
(I)
[0013] wherein Ar is phenyl optionally substituted with 1-3 R6, each
R6 is independently
selected from hydrogen, amino, cyano, halogen, C1-4 alkyl and trifluoromethyl;
[0014] Y is CR3;
4
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0015] Pis CR4;
[0016] W is N;
[0017] R3 is selected from hydrogen and C1-4 alkyl;
[0018] R4 is -(CH2)n-(5-11) membered heterocyclyl, wherein n = 0-6, a
ring-forming S
atom in the heterocyclyl is optionally oxidized to S(0) or S(0)2, a ring-
forming C atom in the
heterocyclyl is optionally oxidized to C(0), and the heterocyclyl is
optionally substituted with
one to more substituents independently selected from C1-3 alkyl and C3-6
cycloalkyl.
[0019] In a second aspect of the present invention, provided is use of
a compound of
general formula (I) or a pharmaceutically acceptable salt, a stereoisomer and
a crystal form
thereof in the treatment of biliary tract cancer:
H
/1\1
)\ r
N
i
\ AT
P,
W
(I)
[0020] wherein the variables in the above general formula (I) are as
defined above.
[0021] In a third aspect of the present invention, provided is a
compound of general
formula (I) or a pharmaceutically acceptable salt, a stereoisomer and a
crystal form thereof for
use in the treatment of biliary tract cancer:
5
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
H
,N
)\ r
FIN N
i
\ Ar
P,
W
(I)
[0022] wherein the variables in the above general formula (I) are as
defined above.
[0023] In a fourth aspect of the present invention, provided is a
method for treating
biliary tract cancer, comprising administering to a patient in need thereof a
therapeutically
effective amount of a compound of formula (I) or a pharmaceutically acceptable
salt, a
stereoisomer and a crystal form thereof:
H
,N
)\ r
FIN N
i
\ Ar
P,
W
(I)
[0024] wherein the variables in the above general formula (I) are as
defined above.
[0025] In a fifth aspect of the present invention, provided is a
pharmaceutical
composition for use in the treatment of biliary tract cancer, comprising a
therapeutically
effective amount of a compound of formula (I) or a pharmaceutically acceptable
salt, a
stereoisomer and a crystal form thereof, and optionally comprising a
pharmaceutically
acceptable carrier:
6
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
H
,N
)\ r
FIN N
/
\ Ar
P,
W
(I)
[0026] wherein the variables in the above general formula (I) are as
defined above.
[0027] 2. Detailed Description of the Invention
[0028] As described above, in the first aspect of the present invention,
provided is use of
a compound of general formula (I) or a pharmaceutically acceptable salt, a
stereoisomer and a
crystal form thereof in the preparation of a medicament for treating biliary
tract cancer:
H
,N
)\ r
FIN N
/
\ Ar
P,
W
(I)
[0029] wherein the variables in the above general formula (I) are as
defined above.
[0030] In one embodiment, Ar is phenyl optionally substituted with 1-3
R6, and each R6
is independently selected from hydrogen and halogen;
[0031] Y is CR3;
[0032] Pis CR4;
[0033] W is N;
7
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0034] R3 is hydrogen;
[0035]
R4 is selected from -(CH2)n-(5-6) membered monocyclic heterocyclyl and
-(CH2)n-(7-11) membered fused heterocyclyl, wherein n = 0-6, a ring-forming S
atom in the
heterocyclyl is optionally oxidized to S(0) or S(0)2, a ring-forming C atom is
optionally
oxidized to C(0), and the heterocyclyl is optionally substituted with one to
more substituents
independently selected from C1-3 alkyl and C3-6 cycloalkyl.
[0036]
In a further embodiment, the (5-6) membered monocyclic heterocyclyl is (5-6)
membered saturated monocyclic heterocyclyl, and the (7-11) membered fused
heterocyclyl is
(7-11) membered saturated fused heterocyclyl. In a preferred embodiment, the
(7-11)
membered fused heterocyclyl is (7-11) membered saturated ortho-fused
heterocyclyl, (7-11)
membered saturated spiro-heterocyclyl or (7-11) membered saturated bridged
heterocyclyl.
)
[0037] In one embodiment, the (5-11) membered heterocyclyl is 0
, N ,
N rli N N
ON ri4j N J'rfj 0 'ffj
N N
if-rf 0 r-r'r Or 0
risj. , and n = 0-3, wherein the heterocyclyl is
,
optionally substituted with one to more substituents independently selected
from C1-3 alkyl and
ni
C3-6 cycloalkyl. In a preferred embodiment, the (5-11) membered heterocyclyl
is 0 ,
(21:1 a 2- ( )1:11 ' H -; 1 '1 1 (
ni 1\T -H,ssc N
KN n Oi\T,1,1,,555
TO4
0
N
N N 0 N)
, ,
rP1 Nl
Or 0
O
, and n = 0-3, wherein the heterocyclyl is optionally
8
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
substituted with one to more substituents independently selected from C1-3
alkyl and C3-6
cycloalkyl.
[0038] In one embodiment, the compound of general formula (I) is a
compound shown in
Table 1 or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof.
Table 1. Compounds of the present invention
No. Structure No. Structure
H II
,N ,N
(
N / N /
)\ )"
HN N HN N 0
2 I
0 \ 7 \ 7
\\
S N N
H
,N H
N /
HN, c
HN N
4 / Cl
\ 7
1<) \
0 N CI N
\
H
H ,N
,N N /
N /
HN, lc HN, I(
5 Cl 6 /N Cl
/
1 N
H H
N ,N
/
)
N- / N \
)\ I
7 HN N HN N
/ Cl 8 I Cl
I N
N N N
N-
9
Date Reeue/Date Received 2022-08-23
CA 03172795 2022-08-23
No. Structure No. Structure
H H
N ,N
N /
9 HN N
/ Cl 10 TIN N Cl
I
N¨ N
H H
N N
N /
HN)\ ic
HN N
11 / Cl 12 / Cl
\ 1
N 7 N 7
H H
,N ,N
N, I( ) (
HN N
HN N
i CI
13 / CI 14
I I
N V N V
0=--S=--0
0õ
1
H H
N ,N
HN N HN N
15 / Cl 16 I Cl
\ / \ I / \
N 7 N V
---N
Date Reeue/Date Received 2022-08-23
CA 03172795 2022-08-23
No. Structure No. Structure
H
H ,N
,N N (
/
IN
N /
Pc T)"N
HN
/ Cl
17 / Cl 18
-,,
\ 7N
\ 7 N
H H
,N ,N
1-1N N FIN N
19 / Cl
20 / Cl
\ 7 N \ 7 N 1 \
---N
H H
,N ,N
MN N
/ Cl 21 FIN N Cl
22 /
-,,
N
H H
,N ,N
N /
HNPc N, (
CI FIN N CI
23 / 24 /
\ 7 I N \ I N
N N --N N N7 N
N N
11
Date Reeue/Date Received 2022-08-23
CA 03172795 2022-08-23
No. Structure No. Structure
H H
,N ,N
N) /- N /
,
HN N CI HN N Cl
25 i 26
\ 7 N
N 7
N N
\ 1
H H
,N N
N N
HN N CI HN N CI
27 / 28 /
\ 7 \ 7
N N HN N
I\\1) I\\1)
y y
H H
N ,N
, (
HN N CI HN N ci
29 I1 30 /
rNN r-NN --N
0) 0)
H H
N ,N
N
HN N IMN N CI
31 -., 32
I 1 1 N
N
12
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
No. Structure No. Structure
H
H N=N CH
=NCH3
N / )\ ( 3
HN N Cl
HN)"(N
/
33 34
CH / Cl
C i
N
1 V \ VN N
0/
H H
N=N ,CF13 N=NCH
3
35 1-1N N Cl 36 1-1N N
Cl
0
0¨ \
N Nv N Nv
H
N-N CH
)\ ( 3 N-NHCH3
)\ /(
HN N
/
37 Cl 38 HN N
/ Cl
\ 7 HI\I7
r-N N
Nõ
H H
-
N-NCI-13 N-I\I -Cf13
HN
lc
40 39 HN N
/ CI / Cl
-,,
I
1\1 1
,
N Nv (R) .rN I\r
(3)
13
Date Reeue/Date Received 2022-08-23
CA 03172795 2022-08-23
No. Structure No. Structure
H
.N õ
N.---k-1-13 H
)\ /( N.I\I---
CH3
HN N )\
/ Cl
HN N
41 42 / Cl
1
N7
1
Ni) (R) 'N N
N
H
H N-NCH3
N.N ---CH3
)\ HN N CI
HN N I
43 / Cl
\
1 7
0 ZN N
N N
N
77v
H H
-
N;NI----CH3
NN CH,- ,
)\
HN N HN N
45 / Cl 46 / Cl
1
1 1
0 0
H H
N-NCH3 N-NCH3
HN N CI HN N Cl
47 / 48 /
\ 7 \ 7
N N N
0 0
14
Date Reeue/Date Received 2022-08-23
CA 03172795 2022-08-23
N-NC1-13
N=N, C 3
HN N IHN N CI
49 II. 1 50
N
rN N
0)
(S) (R)
N-NC1-13
)"(I
HN
/N Cl
51
7
[0039] In a preferred embodiment, the compound of general formula (I)
is
1/
HN N CI
rN N
0) or a pharmaceutically acceptable salt, a stereoisomer
and a crystal
form thereof.
[0040] In one embodiment, the biliary tract cancer refers to
cholangiocarcinoma.
[0041] In a further embodiment, the cholangiocarcinoma refers to an FGFR-
mediated
cholangiocarcinoma. In a preferred embodiment, the FGFR-mediated
cholangiocarcinoma
refers to cholangiocarcinoma mediated by any one of FGFR1, FGFR2 and FGFR3 or
any
combination thereof.
[0042] In another further embodiment, the cholangiocarcinoma refers to
a
cholangiocarcinoma with non-FGFR aberration. In a preferred embodiment, the
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
cholangiocarcinoma with non-FGFR aberration refers to cholangiocarcinoma with
non-FGFR2
aberration.
[0043] In another further embodiment, the cholangiocarcinoma refers to
a
cholangiocarcinoma with FGFR aberration. In a preferred embodiment, the
.. cholangiocarcinoma with FGFR aberration refers to a cholangiocarcinoma with
FGFR2 and/or
FGFR3 aberration.
[0044] In still further embodiments, the cholangiocarcinoma refers to
cholangiocarcinoma with any one of FGFR fusion, FGFR mutation and FGFR
overexpression
or any combination thereof. Wherein the FGFR mutation comprises an FGFR point
mutation
and an FGFR insertion/deletion mutation.
[0045] In a preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma
with any one of FGFR2 fusion, FGFR2 and/or FGFR3 mutation and FGFR
overexpression or
any combination thereof. In another preferred embodiment, the
cholangiocarcinoma refers to
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
cholangiocarcinoma refers to cholangiocarcinoma with FGFR2 and/or FGFR3
mutation. In
another preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma with any
one of FGFR2 N549H, FGFR2 V564F and FGFR3 K650E or any combination thereof.
[0046] In another further embodiment, the cholangiocarcinoma refers to
drug-resistant
cholangiocarcinoma that is positive for FGFR aberration but not responsive to
an FGFR
inhibitor, or drug-resistant cholangiocarcinoma after administration of an
FGFR inhibitor. In a
preferred embodiment, the cholangiocarcinoma refers to a drug-resistant
cholangiocarcinoma
with FGFR2 and/or FGFR3 aberration.
[0047] In another further embodiment, the cholangiocarcinoma refers to
any one of
intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and distal
cholangiocarcinoma
or any combination thereof. In a preferred embodiment, the cholangiocarcinoma
refers to
perihilar cholangiocarcinoma. In a preferred embodiment, the
cholangiocarcinoma refers to
distal cholangiocarcinoma. In a preferred embodiment, the cholangiocarcinoma
refers to
intrahepatic cholangiocarcinoma. In another preferred embodiment, the
intrahepatic
16
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with FGFR2
aberration. In
another preferred embodiment, the intrahepatic cholangiocarcinoma refers to
intrahepatic
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
intrahepatic
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with non-FGFR
aberration.
[0048] In one embodiment, the cholangiocarcinoma further comprises
cholangiocarcinoma mediated by other mechanisms, including Aurora-kinase-
mediated
cholangiocarcinoma and cholangiocarcinoma caused by abnormal IL-6-mediated JAK-
STAT
signaling pathway.
[0049] In one embodiment, the medicament for treating biliary tract
cancer may further
comprise a pharmaceutically acceptable carrier in addition to the compound of
general formula
(I) or the pharmaceutically acceptable salt, the stereoisomer and the crystal
form thereof.
[0050] In one embodiment, the medicament may comprise one or more
pharmaceutically
acceptable carriers, and may be administered to a patient or subject in need
of such treatment by
oral, parenteral, rectal, or transpulmonary administration, and the like. For
oral administration,
the pharmaceutical composition can be prepared into a conventional solid
formulation, such as
tablets, capsules, pills and granules; or can be prepared into an oral liquid
formulation, such as
oral solutions, oral suspensions and syrups. In the preparation of an oral
formulation, an
appropriate filler, binder, disintegrant, lubricant and the like may be added.
For parenteral
administration, the pharmaceutical composition can be prepared into an
injection, including a
solution injection, a sterile powder for injection and a concentrated solution
for injection. The
injection can be produced by a conventional method existing in the
pharmaceutical field, and
during the preparation process, no additive may be added, or an appropriate
additive may be
added according to the property of the medicament. For rectal administration,
the
pharmaceutical composition can be prepared into a suppository and the like.
For
transpulmonary administration, the pharmaceutical composition can be prepared
into an
inhalant, a spray or the like.
[0051] In one embodiment, the medicament for treating biliary tract
cancer further
comprises one or more second therapeutically active agents in addition to the
compound of
17
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
general formula (I) or the pharmaceutically acceptable salt, the stereoisomer
and the crystal
form thereof.
[0052] In a further embodiment, the second therapeutically active
agent is an
antimetabolite, a growth factor inhibitor, a mitotic inhibitor, an anti-tumor
hormone, an
alkylating agent, metallic platinum, a topoisomerase inhibitor, a hormonal
drug, an
immunomodulator, a tumor suppressor gene, a cancer vaccine, or an immune
checkpoint
inhibitor.
[0053] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment in
combination.
[0054] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment
sequentially,
simultaneously or in a combined formulation.
[0055] In a further embodiment, the patient or subject is a mammal. In a
preferred
embodiment, the patient or subject is a human.
[0056] In a second aspect of the present invention, provided is a
compound of general
formula (I) or a pharmaceutically acceptable salt, a stereoisomer and a
crystal form thereof for
use in the treatment of biliary tract cancer,
H
,N
)\ r
FIN N
i
\ Ar
P,
W
(I)
[0057] wherein the variables in the above general formula (I) are as
defined above.
18
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0058] In one embodiment, Ar is phenyl optionally substituted with 1-3
R6, and each R6
is independently selected from hydrogen and halogen;
[0059] Y is CR3;
[0060] P is CR4;
[0061] W is N;
[0062] R3 is hydrogen;
[0063] R4 is selected from -(CH2)n-(5-6) membered monocyclic
heterocyclyl and
-(CH2)n-(7-11) membered fused heterocyclyl, wherein n = 0-6, a ring-forming S
atom in the
heterocyclyl is optionally oxidized to S(0) or S(0)2, a ring-forming C atom is
optionally
oxidized to C(0), and the heterocyclyl is optionally substituted with one to
more substituents
independently selected from C1-3 alkyl and C3-6 cycloalkyl.
[0064] In a further embodiment, the (5-6) membered monocyclic
heterocyclyl is (5-6)
membered saturated monocyclic heterocyclyl, and the (7-11) membered fused
heterocyclyl is
(7-11) membered saturated fused heterocyclyl. In a preferred embodiment, the
(7-11)
membered fused heterocyclyl is (7-11) membered saturated ortho-fused
heterocyclyl, (7-11)
membered saturated spiro-heterocyclyl or (7-11) membered saturated bridged
heterocyclyl.
o1 n
[0065] In one embodiment, the (5-11) membered heterocyclyl is 0 N)
) )\11
0 0/ jON rj
N( n
0 \ X - n
f=P'r rfjj' Or 0 r , and n = 0-3, wherein the
heterocyclyl is
optionally substituted with one to more substituents independently selected
from C1-3 alkyl and
C3-6 cycloalkyl. In a preferred embodiment, the (5-11) membered heterocyclyl
is 0
19
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
(<n q1111 qn\
1:1)s
N'eti
0/ N/
(2
Orlf Or 0
, and n = 0-3, wherein the heterocyclyl is optionally
substituted with one to more substituents independently selected from C1-3
alkyl and C3-6
cycloalkyl.
[0066] In one embodiment, the compound of general formula (I) is a compound
shown in
Table 1 or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof.
[0067] In a preferred embodiment, the compound of general formula (I)
is
N
HN N Cl
rN N
0 or a pharmaceutically acceptable salt, a stereoisomer
and a crystal
form thereof.
[0068] In one embodiment, the biliary tract cancer refers to
cholangiocarcinoma.
[0069] In a further embodiment, the cholangiocarcinoma refers to an
FGFR-mediated
cholangiocarcinoma. In a preferred embodiment, the FGFR-mediated
cholangiocarcinoma
refers to cholangiocarcinoma mediated by any one of FGFR1, FGFR2 and FGFR3 or
any
combination thereof.
[0070] In another further embodiment, the cholangiocarcinoma refers to a
cholangiocarcinoma with non-FGFR aberration. In a preferred embodiment, the
cholangiocarcinoma with non-FGFR aberration refers to cholangiocarcinoma with
non-FGFR2
aberration.
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0071] In another further embodiment, the cholangiocarcinoma refers to
a
cholangiocarcinoma with FGFR aberration. In a preferred embodiment, the
cholangiocarcinoma with FGFR aberration refers to a cholangiocarcinoma with
FGFR2 and/or
FGFR3 aberration.
[0072] In still further embodiments, the cholangiocarcinoma refers to
cholangiocarcinoma with any one of FGFR fusion, FGFR mutation and FGFR
overexpression
or any combination thereof. Wherein the FGFR mutation comprises an FGFR point
mutation
and an FGFR insertion/deletion mutation.
[0073] In a preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma
with any one of FGFR2 fusion, FGFR2 and/or FGFR3 mutation and FGFR
overexpression or
any combination thereof. In another preferred embodiment, the
cholangiocarcinoma refers to
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
cholangiocarcinoma refers to cholangiocarcinoma with FGFR2 and/or FGFR3
mutation. In
another preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma with any
one of FGFR2 N549H, FGFR2 V564F and FGFR3 K650E or any combination thereof.
[0074] In another further embodiment, the cholangiocarcinoma refers to
drug-resistant
cholangiocarcinoma that is positive for FGFR aberration but not responsive to
an FGFR
inhibitor, or drug-resistant cholangiocarcinoma after administration of an
FGFR inhibitor. In a
preferred embodiment, the cholangiocarcinoma refers to drug-resistant
cholangiocarcinoma
with FGFR2 and/or FGFR3 aberration.
[0075] In another further embodiment, the cholangiocarcinoma refers to
any one of
intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and distal
cholangiocarcinoma
or any combination thereof. In a preferred embodiment, the cholangiocarcinoma
refers to
perihilar cholangiocarcinoma. In a preferred embodiment, the
cholangiocarcinoma refers to
distal cholangiocarcinoma. In a preferred embodiment, the cholangiocarcinoma
refers to
intrahepatic cholangiocarcinoma. In another preferred embodiment, the
intrahepatic
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with FGFR2
aberration . In
another preferred embodiment, the intrahepatic cholangiocarcinoma refers to
intrahepatic
21
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
intrahepatic
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with non-FGFR
aberration.
[0076] In one embodiment, the cholangiocarcinoma further comprises
cholangiocarcinoma mediated by other mechanisms, including Aurora-kinase-
mediated
cholangiocarcinoma and cholangiocarcinoma caused by abnormal IL-6-mediated JAK-
STAT
signaling pathway.
[0077] In one embodiment, the use comprises administering to a patient
or subject in
need thereof a therapeutically effective amount of a compound of general
formula (I) or a
pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof.
[0078] In one embodiment, a therapeutically effective amount of the
compound of
general formula (I) or the pharmaceutically acceptable salt, the stereoisomer
and the crystal
form thereof may be further prepared with one or more pharmaceutically
acceptable carriers
into any pharmaceutically acceptable pharmaceutical formulation.
[0079] In one embodiment, the pharmaceutical formulation may comprise
one or more
pharmaceutically acceptable carriers, and may be administered to a patient or
subject in need of
such treatment by oral, parenteral, rectal, or transpulmonary administration,
and the like. For
oral administration, the pharmaceutical composition can be prepared into a
conventional solid
formulation, such as tablets, capsules, pills and granules; or can be prepared
into an oral liquid
formulation, such as oral solutions, oral suspensions and syrups. In the
preparation of an oral
formulation, an appropriate filler, binder, disintegrant, lubricant and the
like may be added. For
parenteral administration, the pharmaceutical composition can be prepared into
an injection,
including a solution injection, a sterile powder for injection and a
concentrated solution for
injection. The injection can be produced by a conventional method existing in
the
pharmaceutical field, and during the preparation process, no additive may be
added, or an
appropriate additive may be added according to the property of the medicament.
For rectal
administration, the pharmaceutical composition can be prepared into a
suppository and the like.
For transpulmonary administration, the pharmaceutical composition can be
prepared into an
inhalant, a spray or the like.
22
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0080] In one embodiment, the use further comprises administering to a
patient or subject
in need thereof a therapeutically effective amount of a compound of general
formula (I) or a
pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof
and one or more
second therapeutically active agents.
[0081] In a further embodiment, the second therapeutically active agent is
an
antimetabolite, a growth factor inhibitor, a mitotic inhibitor, an anti-tumor
hormone, an
alkylating agent, metallic platinum, a topoisomerase inhibitor, a hormonal
drug, an
immunomodulator, a tumor suppressor gene, a cancer vaccine, or an immune
checkpoint
inhibitor.
[0082] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment in
combination.
[0083] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment
sequentially,
simultaneously or in a combined formulation.
[0084] In a further embodiment, the patient or subject is a mammal. In
a preferred
embodiment, the patient or subject is a human.
[0085] In a third aspect of the present invention, provided is a
compound of general
formula (I) or a pharmaceutically acceptable salt, a stereoisomer and a
crystal form thereof for
use in the treatment of biliary tract cancer:
H
/1\1
)\ r
N
i
\ Ar
P,
W
23
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
(I)
[0086] wherein the variables in the above general formula (I) are as
defined above.
[0087] In one embodiment, Ar is phenyl optionally substituted with 1-3
R6, and each R6
is independently selected from hydrogen and halogen;
[0088] Y 1 S CR3;
[0089] P is CR4;
[0090] W is N;
[0091] R3 is hydrogen;
[0092] R4 is selected from -(CH2)n-(5-6) membered monocyclic
heterocyclyl and
-(C112)n-(7-11) membered fused heterocyclyl, wherein n = 0-6, a ring-forming S
atom in the
heterocyclyl is optionally oxidized to S(0) or S(0)2, a ring-forming C atom is
optionally
oxidized to C(0), and the heterocyclyl is optionally substituted with one to
more substituents
independently selected from C1-3 alkyl and C3-6 cycloalkyl.
[0093] In a further embodiment, the (5-6) membered monocyclic
heterocyclyl is (5-6)
membered saturated monocyclic heterocyclyl, and the (7-11) membered fused
heterocyclyl is
(7-11) membered saturated fused heterocyclyl. In a preferred embodiment, the
(7-11)
membered fused heterocyclyl is (7-11) membered saturated ortho-fused
heterocyclyl, (7-11)
membered saturated spiro-heterocyclyl or (7-11) membered saturated bridged
heterocyclyl.
c)r)ril Cfr)ril
)
[0094] In one embodiment, the (5-11) membered heterocyclyl is 0 , N
,
N
0,(-1(,)õ, N N
...-- =-,,
( 1 On 1 Rn qn 0\11
o) ,,,ri ,S ,,,,,, '\.,,ri
ID N , 0 N
(in N N
' ( \rt
(i)
,-r'r: , 0 cs' Or 0
irjsr , and n = 0-3, wherein the heterocyclyl is
optionally substituted with one to more substituents independently selected
from C1-3 alkyl and
24
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
n
C3-6 cycloalkyl. In a preferred embodiment, the (5-11) membered heterocyclyl
is 0 ,
\
(<n H-i'llt' H-11 (
Os N'hri
N 0 0/ -1\1 N/ N 0 O
(2
0113N - hi'jc s $ s Or 0
, and n = 0-3, wherein the heterocyclyl is optionally
substituted with one to more substituents independently selected from C1-3
alkyl and C3-6
cycloalkyl.
[0095]
In one embodiment, the compound of general formula (I) is a compound shown in
Table 1 or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof.
[0096]
In a preferred embodiment, the compound of general formula (I) is
H
,N
N i
)"(
HN N Cl
/
\ 7
rN N
0
or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof.
[0097] In one embodiment, the biliary tract cancer refers to
cholangiocarcinoma.
[0098]
In a further embodiment, the cholangiocarcinoma refers to an FGFR-mediated
cholangiocarcinoma. In a preferred embodiment, the FGFR-mediated
cholangiocarcinoma
refers to cholangiocarcinoma mediated by any one of FGFR1, FGFR2 and FGFR3 or
any
combination thereof.
[0099]
In another further embodiment, the cholangiocarcinoma refers to a
cholangiocarcinoma with non-FGFR aberration. In a preferred embodiment, the
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
cholangiocarcinoma with non-FGFR aberration refers to a cholangiocarcinoma
with
non-FGFR2 aberration.
[0100] In another further embodiment, the cholangiocarcinoma refers to
a
cholangiocarcinoma with FGFR aberration. In a preferred embodiment, the
cholangiocarcinoma with FGFR aberration refers to a cholangiocarcinoma with
FGFR2 and/or
FGFR3 aberration.
[0101] In still further embodiments, the cholangiocarcinoma refers to
cholangiocarcinoma with any one of FGFR fusion, FGFR mutation and FGFR
overexpression
or any combination thereof. Wherein the FGFR mutation comprises an FGFR point
mutation
and an FGFR insertion/deletion mutation.
[0102] In a preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma
with any one of FGFR2 fusion, FGFR2 and/or FGFR3 mutation and FGFR
overexpression or
any combination thereof. In another preferred embodiment, the
cholangiocarcinoma refers to
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
cholangiocarcinoma refers to cholangiocarcinoma with FGFR2 and/or FGFR3
mutation. In
another preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma with any
one of FGFR2 N549H, FGFR2 V564F and FGFR3 K650E or any combination thereof.
[0103] In another further embodiment, the cholangiocarcinoma refers to
drug-resistant
cholangiocarcinoma that is positive for FGFR aberration but not responsive to
an FGFR
inhibitor, or drug-resistant cholangiocarcinoma after administration of an
FGFR inhibitor. In a
preferred embodiment, the cholangiocarcinoma refers to drug-resistant
cholangiocarcinoma
with FGFR2 and/or FGFR3 aberration.
[0104] In another further embodiment, the cholangiocarcinoma refers to
any one of
intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and distal
cholangiocarcinoma
or any combination thereof. In a preferred embodiment, the cholangiocarcinoma
refers to
perihilar cholangiocarcinoma. In a preferred embodiment, the
cholangiocarcinoma refers to
distal cholangiocarcinoma. In a preferred embodiment, the cholangiocarcinoma
refers to
intrahepatic cholangiocarcinoma. In another preferred embodiment, the
intrahepatic
26
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with FGFR2
aberration. In
another preferred embodiment, the intrahepatic cholangiocarcinoma refers to
intrahepatic
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
intrahepatic
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with non-FGFR
aberration.
[0105] In one embodiment, the cholangiocarcinoma further comprises
cholangiocarcinoma mediated by other mechanisms, including Aurora-kinase-
mediated
cholangiocarcinoma and cholangiocarcinoma caused by abnormal IL-6-mediated JAK-
STAT
signaling pathway.
[0106] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof is administered
in a
therapeutically effective amount to a patient or subject in need thereof.
[0107] In one embodiment, a therapeutically effective amount of the
compound of
general formula (I) or the pharmaceutically acceptable salt, the stereoisomer
and the crystal
form thereof may be further prepared with one or more pharmaceutically
acceptable carriers
into any pharmaceutically acceptable pharmaceutical formulation.
[0108] In one embodiment, the pharmaceutical formulation may comprise
one or more
pharmaceutically acceptable carriers, and may be administered to a patient or
subject in need of
such treatment by oral, parenteral, rectal, or transpulmonary administration,
and the like. For
oral administration, the pharmaceutical composition can be prepared into a
conventional solid
formulation, such as tablets, capsules, pills and granules; or can be prepared
into an oral liquid
formulation, such as oral solutions, oral suspensions and syrups. In the
preparation of an oral
formulation, an appropriate filler, binder, disintegrant, lubricant and the
like may be added. For
parenteral administration, the pharmaceutical composition can be prepared into
an injection,
including a solution injection, a sterile powder for injection and a
concentrated solution for
injection. The injection can be produced by a conventional method existing in
the
pharmaceutical field, and during the preparation process, no additive may be
added, or an
appropriate additive may be added according to the property of the medicament.
For rectal
administration, the pharmaceutical composition can be prepared into a
suppository and the like.
27
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
For transpulmonary administration, the pharmaceutical composition can be
prepared into an
inhalant, a spray or the like.
[0109] In one embodiment, a therapeutically effective amount of a
compound of general
formula (I) or a pharmaceutically acceptable salt, a stereoisomer and a
crystal form thereof can
.. further be administered in combination with one or more second
therapeutically active agents to
a patient or subject in need thereof.
[0110] In a further embodiment, the second therapeutically active
agent is an
antimetabolite, a growth factor inhibitor, a mitotic inhibitor, an anti-tumor
hormone, an
alkylating agent, metallic platinum, a topoisomerase inhibitor, a hormonal
drug, an
immunomodulator, a tumor suppressor gene, a cancer vaccine, or an immune
checkpoint
inhibitor.
[0111] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment in
combination.
[0112] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment
sequentially,
simultaneously or in a combined formulation.
[0113] In a further embodiment, the patient or subject is a mammal. In
a preferred
embodiment, the patient or subject is a human.
[0114] In a fourth aspect of the present invention, provided is a
method for treating
biliary tract cancer, comprising administering to a patient in need thereof a
therapeutically
effective amount of a compound of formula (I) or a pharmaceutically acceptable
salt, a
stereoisomer and a crystal form thereof,
28
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
H
,N
N
)\ r
FIN /.1
\ AT
P,
W
(I)
[0115] wherein the variables in the above general formula (I) are as
defined above.
[0116] In one embodiment, Ar is phenyl optionally substituted with 1-3
R6, and each R6
is independently selected from hydrogen and halogen;
[0117] Y is CR3;
[0118] P is CR4;
[0119] W is N;
[0120] R3 is hydrogen;
[0121] R4 is selected from -(CH2)n-(5-6) membered monocyclic heterocyclyl
and
-(CH2)n-(7-11) membered fused heterocyclyl, wherein n = 0-6, a ring-forming S
atom in the
heterocyclyl is optionally oxidized to S(0) or S(0)2, a ring-forming C atom is
optionally
oxidized to C(0), and the heterocyclyl is optionally substituted with one to
more substituents
independently selected from C1-3 alkyl and C3-6 cycloalkyl.
[0122] In a further embodiment, the (5-6) membered monocyclic heterocyclyl
is (5-6)
membered saturated monocyclic heterocyclyl, and the (7-11) membered fused
heterocyclyl is
(7-11) membered saturated fused heterocyclyl. In a preferred embodiment, the
(7-11)
membered fused heterocyclyl is (7-11) membered saturated ortho-fused
heterocyclyl, (7-11)
membered saturated spiro-heterocyclyl or (7-11) membered saturated bridged
heterocyclyl.
29
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
C}C)11 C}C)11
)
[0123] In one
embodiment, the (5-11) membered heterocyclyl is 0 , N,
N
0,(>i On N ( 4n ) , qn ( )\11 ( n
.. 1 qn
-,S N Isj N
ON
aN ________ N N(\n
__________ r, 0 ri'rj 0 rris
Or
, and n = 0-3, wherein the heterocyclyl is
,
optionally substituted with one to more substituents independently selected
from C1-3 alkyl and
n
0
C3-6 cycloalkyl. In a preferred embodiment, the (5-11) membered heterocyclyl
is ,
( <:- - ( ') '' ri ( )?111-1 (
(N)
N'eti
o // --, ---
N 0 N N) N 0 O
Niissss N -64
Orij 0
Or
, and n = 0-3, wherein the heterocyclyl is optionally
substituted with one to more substituents independently selected from C1-3
alkyl and C3-6
cycloalkyl.
[0124] In one embodiment, the compound of general formula (I) is a compound
shown in
Table 1 or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof.
[0125]
In a preferred embodiment, the compound of general formula (I) is
H
,N
N
)\
HN N Cl
/
\ ,
rN N
0)
or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof.
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0126] In one embodiment, the biliary tract cancer refers to
cholangiocarcinoma.
[0127] In a further embodiment, the cholangiocarcinoma refers to an
FGFR-mediated
cholangiocarcinoma. In a preferred embodiment, the FGFR-mediated
cholangiocarcinoma
refers to cholangiocarcinoma mediated by any one of FGFR1, FGFR2 and FGFR3 or
any
combination thereof.
[0128] In another further embodiment, the cholangiocarcinoma refers to
a
cholangiocarcinoma with non-FGFR aberration. In a preferred embodiment, the
cholangiocarcinoma with non-FGFR aberration refers to cholangiocarcinoma with
non-FGFR2
aberration.
[0129] In another further embodiment, the cholangiocarcinoma refers to a
cholangiocarcinoma with FGFR aberration. In a preferred embodiment, the
cholangiocarcinoma with FGFR aberration refers to a cholangiocarcinoma with
FGFR2 and/or
FGFR3 aberration.
[0130] In still further embodiments, the cholangiocarcinoma refers to
cholangiocarcinoma with any one of FGFR fusion, FGFR mutation and FGFR
overexpression
or any combination thereof. Wherein the FGFR mutation comprises an FGFR point
mutation
and an FGFR insertion/deletion mutation.
[0131] In a preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma
with any one of FGFR2 fusion, FGFR2 and/or FGFR3 mutation and FGFR
overexpression or
any combination thereof. In another preferred embodiment, the
cholangiocarcinoma refers to
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
cholangiocarcinoma refers to cholangiocarcinoma with FGFR2 and/or FGFR3
mutation. In
another preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma with any
one of FGFR2 N549H, FGFR2 V564F and FGFR3 K650E or any combination thereof.
[0132] In another further embodiment, the cholangiocarcinoma refers to drug-
resistant
cholangiocarcinoma that is positive for FGFR aberration but not responsive to
an FGFR
inhibitor, or drug-resistant cholangiocarcinoma after administration of an
FGFR inhibitor. In a
31
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
preferred embodiment, the cholangiocarcinoma refers to drug-resistant
cholangiocarcinoma
with FGFR2 and/or FGFR3 aberration.
[0133] In another further embodiment, the cholangiocarcinoma refers to
any one of
intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and distal
cholangiocarcinoma
or any combination thereof. In a preferred embodiment, the cholangiocarcinoma
refers to
perihilar cholangiocarcinoma. In a preferred embodiment, the
cholangiocarcinoma refers to
distal cholangiocarcinoma. In a preferred embodiment, the cholangiocarcinoma
refers to
intrahepatic cholangiocarcinoma. In another preferred embodiment, the
intrahepatic
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with FGFR2
aberration . In
another preferred embodiment, the intrahepatic cholangiocarcinoma refers to
intrahepatic
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
intrahepatic
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with non-FGFR
aberration.
[0134] In one embodiment, the cholangiocarcinoma further comprises
cholangiocarcinoma mediated by other mechanisms, including Aurora-kinase-
mediated
cholangiocarcinoma and cholangiocarcinoma caused by abnormal IL-6-mediated JAK-
STAT
signaling pathway.
[0135] In one embodiment, the therapeutically effective amount of the
compound of
general formula (I) or a pharmaceutically acceptable salt, a stereoisomer and
a crystal form
thereof may be further prepared with one or more pharmaceutically acceptable
carriers into any
pharmaceutically acceptable pharmaceutical formulation.
[0136] In one embodiment, the pharmaceutical formulation may comprise
one or more
pharmaceutically acceptable carriers, and may be administered to a patient or
subject in need of
such treatment by oral, parenteral, rectal, or transpulmonary administration,
and the like. For
oral administration, the pharmaceutical composition can be prepared into a
conventional solid
formulation, such as tablets, capsules, pills and granules; or can be prepared
into an oral liquid
formulation, such as oral solutions, oral suspensions and syrups. In the
preparation of an oral
formulation, an appropriate filler, binder, disintegrant, lubricant and the
like may be added. For
parenteral administration, the pharmaceutical composition can be prepared into
an injection,
32
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
including a solution injection, a sterile powder for injection and a
concentrated solution for
injection. The injection can be produced by a conventional method existing in
the
pharmaceutical field, and during the preparation process, no additive may be
added, or an
appropriate additive may be added according to the property of the medicament.
For rectal
administration, the pharmaceutical composition can be prepared into a
suppository and the like.
For transpulmonary administration, the pharmaceutical composition can be
prepared into an
inhalant, a spray or the like.
[0137] In one embodiment, the method further comprises administering
to a patient or
subject in need thereof a therapeutically effective amount of a compound of
general formula (I)
or a pharmaceutically acceptable salt, a stereoisomer and a crystal form
thereof and one or more
second therapeutically active agents.
[0138] In a further embodiment, the second therapeutically active
agent is an
antimetabolite, a growth factor inhibitor, a mitotic inhibitor, an anti-tumor
hormone, an
alkylating agent, metallic platinum, a topoisomerase inhibitor, a hormonal
drug, an
immunomodulator, a tumor suppressor gene, a cancer vaccine, or an immune
checkpoint
inhibitor.
[0139] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment in
combination.
[0140] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment
sequentially,
simultaneously or in a combined formulation.
[0141] In a further embodiment, the patient or subject is a mammal. In
a preferred
embodiment, the patient or subject is a human.
[0142] In a fifth aspect of the present invention, provided is a
pharmaceutical
composition for use in the treatment of biliary tract cancer, comprising a
therapeutically
effective amount of a compound of formula (I) or a pharmaceutically acceptable
salt, a
33
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
stereoisomer and a crystal form thereof, and optionally comprising a
pharmaceutically
acceptable carrier:
H
,N
)\ r
N
/
\ AT
P,
W
(I)
[0143] wherein the variables in the above general formula (I) are as
defined above.
[0144] In one embodiment, Ar is phenyl optionally substituted with 1-3
R6, and each R6
is independently selected from hydrogen and halogen;
[0145] Y is CR3;
[0146] Pis CR4;
[0147] W is N;
[0148] R3 is hydrogen;
[0149] R4 is selected from -(C112)n-(5-6) membered monocyclic
heterocyclyl and
-(C112)n-(7-1 1) membered fused heterocyclyl, wherein n = 0-6, a ring-forming
S atom in the
heterocyclyl is optionally oxidized to S(0) or S(0)2, a ring-forming C atom is
optionally
oxidized to C(0), and the heterocyclyl is optionally substituted with one to
more substituents
independently selected from C1-3 alkyl and C3-6 cycloalkyl.
[0150] In a further embodiment, the (5-6) membered monocyclic
heterocyclyl is (5-6)
membered saturated monocyclic heterocyclyl, and the (7-11) membered fused
heterocyclyl is
(7-11) membered saturated fused heterocyclyl. In a preferred embodiment, the
(7-11)
membered fused heterocyclyl is (7-11) membered saturated ortho-fused
heterocyclyl, (7-11)
membered saturated spiro-heterocyclyl or (7-11) membered saturated bridged
heterocyclyl.
34
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
C}C)11 C}C)11
)
[0151] In one
embodiment, the (5-11) membered heterocyclyl is 0 , N,
N
0,r>i On N N
) qn ( )\11 On ( n 10\n
-,S jµj'rjN Isj ON
N
,-i'r 0 pi's. 0 i-r='''
Or
, and n = 0-3, wherein the heterocyclyl is
,
optionally substituted with one to more substituents independently selected
from C1-3 alkyl and
n
0
C3-6 cycloalkyl. In a preferred embodiment, the (5-11) membered heterocyclyl
is ,
( <:- - (').';11' ( )?111-1 (
N
N'eti
o // --, ---
N 0 N N N 0 O
Orij 0
Or
, and n = 0-3, wherein the heterocyclyl is optionally
substituted with one to more substituents independently selected from C1-3
alkyl and C3-6
cycloalkyl.
[0152] In one embodiment, the compound of general formula (I) is a compound
shown in
Table 1 or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof.
[0153]
In a preferred embodiment, the compound of general formula (I) is
H
, N
N /
)"(
HN N CI
/
\ ,
rN N
0
or a pharmaceutically acceptable salt, a stereoisomer and a crystal
form thereof.
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0154] In one embodiment, the biliary tract cancer refers to
cholangiocarcinoma.
[0155] In a further embodiment, the cholangiocarcinoma refers to an
FGFR-mediated
cholangiocarcinoma. In a preferred embodiment, the FGFR-mediated
cholangiocarcinoma
refers to cholangiocarcinoma mediated by any one of FGFR1, FGFR2 and FGFR3 or
any
combination thereof.
[0156] In another further embodiment, the cholangiocarcinoma refers to
a
cholangiocarcinoma with non-FGFR aberration. In a preferred embodiment, the
cholangiocarcinoma with non-FGFR aberration refers to cholangiocarcinoma with
non-FGFR2
aberration.
[0157] In another further embodiment, the cholangiocarcinoma refers to a
cholangiocarcinoma with FGFR aberration. In a preferred embodiment, the
cholangiocarcinoma with FGFR aberration refers to a cholangiocarcinoma with
FGFR2 and/or
FGFR3 aberration.
[0158] In still further embodiments, the cholangiocarcinoma refers to
cholangiocarcinoma with any one of FGFR fusion, FGFR mutation and FGFR
overexpression
or any combination thereof. Wherein the FGFR mutation comprises an FGFR point
mutation
and an FGFR insertion/deletion mutation.
[0159] In a preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma
with any one of FGFR2 fusion, FGFR2 and/or FGFR3 mutation and FGFR
overexpression or
any combination thereof. In another preferred embodiment, the
cholangiocarcinoma refers to
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
cholangiocarcinoma refers to cholangiocarcinoma with FGFR2 and/or FGFR3
mutation. In
another preferred embodiment, the cholangiocarcinoma refers to
cholangiocarcinoma with any
one of FGFR2 N549H, FGFR2 V564F and FGFR3 K650E or any combination thereof.
[0160] In another further embodiment, the cholangiocarcinoma refers to drug-
resistant
cholangiocarcinoma that is positive for FGFR aberration but not responsive to
an FGFR
inhibitor, or drug-resistant cholangiocarcinoma after administration of an
FGFR inhibitor. In a
36
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
preferred embodiment, the cholangiocarcinoma refers to drug-resistant
cholangiocarcinoma
with FGFR2 and/or FGFR3 aberration.
[0161] In another further embodiment, the cholangiocarcinoma refers to
any one of
intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and distal
cholangiocarcinoma
or any combination thereof. In a preferred embodiment, the cholangiocarcinoma
refers to
perihilar cholangiocarcinoma. In a preferred embodiment, the
cholangiocarcinoma refers to
distal cholangiocarcinoma. In a preferred embodiment, the cholangiocarcinoma
refers to
intrahepatic cholangiocarcinoma. In another preferred embodiment, the
intrahepatic
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with FGFR2
aberration. In
another preferred embodiment, the intrahepatic cholangiocarcinoma refers to
intrahepatic
cholangiocarcinoma with FGFR2 fusion. In another preferred embodiment, the
intrahepatic
cholangiocarcinoma refers to intrahepatic cholangiocarcinoma with non-FGFR
aberration.
[0162] In one embodiment, the cholangiocarcinoma further comprises
cholangiocarcinoma mediated by other mechanisms, including Aurora-kinase-
mediated
cholangiocarcinoma and cholangiocarcinoma caused by abnormal IL-6-mediated JAK-
STAT
signaling pathway.
[0163] In one embodiment, the compound of general formula (I) or a
pharmaceutically
acceptable salt, a stereoisomer and a crystal form thereof can be further
prepared with one or
more pharmaceutically acceptable carriers into any pharmaceutically acceptable
pharmaceutical formulation.
[0164] In one embodiment, the pharmaceutical formulation may comprise
one or more
pharmaceutically acceptable carriers, and may be administered to a patient or
subject in need of
such treatment by oral, parenteral, rectal, or transpulmonary administration,
and the like. For
oral administration, the pharmaceutical composition can be prepared into a
conventional solid
formulation, such as tablets, capsules, pills and granules; or can be prepared
into an oral liquid
formulation, such as oral solutions, oral suspensions and syrups. In the
preparation of an oral
formulation, an appropriate filler, binder, disintegrant, lubricant and the
like may be added. For
parenteral administration, the pharmaceutical composition can be prepared into
an injection,
37
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
including a solution injection, a sterile powder for injection and a
concentrated solution for
injection. The injection can be produced by a conventional method existing in
the
pharmaceutical field, and during the preparation process, no additive may be
added, or an
appropriate additive may be added according to the property of the medicament.
For rectal
administration, the pharmaceutical composition can be prepared into a
suppository and the like.
For transpulmonary administration, the pharmaceutical composition can be
prepared into an
inhalant, spray or the like.
[0165] In one embodiment, the pharmaceutical composition further
comprises one or
more second therapeutically active agents.
[0166] In a further embodiment, the second therapeutically active agent is
an
antimetabolite, a growth factor inhibitor, a mitotic inhibitor, an anti-tumor
hormone, an
alkylating agent, metallic platinum, a topoisomerase inhibitor, a hormonal
drug, an
immunomodulator, a tumor suppressor gene, a cancer vaccine, or an immune
checkpoint
inhibitor.
[0167] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment in
combination.
[0168] In one embodiment, the compound of general formula (I) or the
pharmaceutically
acceptable salt, the stereoisomer and the crystal form thereof and the second
therapeutically
active agent are administered to a patient or subject in need of treatment
sequentially,
simultaneously or in a combined formulation.
[0169] In a further embodiment, the patient or subject is a mammal. In
a preferred
embodiment, the patient or subject is a human.
[0170] 3. Definition
[0171] The "halogen" described herein refers to fluorine, chlorine,
bromine, iodine and
the like, and preferably fluorine and chlorine.
38
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0172] The "halogenated" described herein means that any hydrogen atom
in a
substituent can be substituted with one or more identical or different
halogen. "Halogen" is
defined as above.
[0173] The "cyano" described herein referred to the -CN group.
[0174] The "amino" described herein refers to the -NH2 group.
[0175] As described herein, "Ci-4 alkyl" refers to a linear or
branched alkyl derived from
a hydrocarbon moiety having 1 to 4 carbon atoms by removing one hydrogen atom,
such as
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-
butyl. The "Ci-3 alkyl"
refers to the above alkyl having 1 to 3 carbon atoms.
[0176] The "C3-6 cycloalkyl" described herein refers to a monocyclic
cycloalkyl or
bicyclic cycloalkyl system or a polycyclic cycloalkyl system having 3 to 6
carbon atoms. These
groups are saturated but not aromatic, including monocyclic and fused ring
structures which
can be formed, unless otherwise specified. Examples thereof include, but are
not limited to:
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
bi cyc lo [2 .2. 2]h exane, and
bicyclo[3.2.1]hexane.
[0177] The "5-11 membered heterocyclyl" described herein refers to a
non-aromatic
cyclic group having 5 to 11 ring carbon atoms, wherein at least one ring
carbon atom is
substituted with one or more heteroatoms selected from 0, S and N, and
preferably 1 to 3
heteroatoms, and ring-forming atoms including carbon atoms, nitrogen atoms and
sulfur atoms
may be oxidized.
[0178] The "heterocyclyl" refers to a monocyclic heterocyclyl or
bicyclic heterocyclyl
system or a polycyclic heterocyclyl system, including saturated and partially
saturated
heterocyclyl, but not including aromatic rings. Unless otherwise specified,
the "5-11 membered
heterocyclyl" described herein includes monocyclic and fused ring structures
which can be
formed.
[0179] The monocyclic heterocyclyl may be 5-7 membered heterocyclyl, 5-
6 membered
heterocyclyl, 5-6 membered oxygen-containing heterocyclyl, 5-6 membered
39
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
nitrogen-containing heterocyclyl, 5-6 membered saturated heterocyclyl and the
like. Examples
of 5-6 membered monocyclic heterocyclyl described herein include, but are not
limited to,
tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydrothienyl, imidazolidinyl,
pyrazolidinyl,
1,2-oxazolidinyl, 1,3-oxazolidinyl, 1,2-thiazolidinyl, 1,3-thiazolidinyl,
tetrahydro-2H-pyranyl,
tetrahydro-2H-thiopyranyl, piperidinyl, piperazinyl, morpholinyl, 1,4-
dioxanyl,
1 ,4-oxathi anyl, 4,5-dihydroisoxazolyl,
4,5-dihydrooxazolyl, 2,5-dihydroox az olyl,
2,3 -dihydro oxazolyl, 3,4-dihydro-2H-pyrrolyl,
2,3 -dihydro- 1H-pyrrolyl,
2,5-dihydro- 1H-imidazolyl, 4,5-dihydro-1H-imidazolyl,
4,5-di hydro- 1H-pyrazolyl,
4,5-dihydro-3H-pyrazolyl, 4,5-dihydrothiazolyl,
2,5-dihydrothiazolyl, 2H-pyranyl,
4H-pyranyl, 2H-thiopyranyl, 4H-thiopyranyl, 2,3,4,5-tetrahydropyridyl, 1,2-
isoxazolyl,
1,4-isoxazolyl, 6H-1,3-oxazinyl, or the like.
[0180]
The fused heterocyclyl includes ortho-fused heterocyclyl, spiro-heterocyclyl
and
bridged heterocyclyl, which may be saturated, partially saturated or
unsaturated, but
non-aromatic. Unless otherwise specified, the 7-11 membered fused heterocyclyl
described
herein includes ortho-fused, spiro and bridged structures which can be formed.
[0181]
The ortho-fused heterocyclyl may be 7-11 membered ortho-fused cyclyl, and
preferably 7-11 membered saturated ortho-fused cyclyl; examples of which
include, but are not
limited to: 3 ,6-di azabi cyclo[3 .2
.0]heptyl, 3,8-di azabicyclo [4.2. O]octyl,
3 ,7-di azabi cycl o [4 .2.0] octyl, octahydropyrrolo [3 ,4-c] pyrroly, octahy
dropyrrol o [3 ,4-b]pyrroly,
octahydropyrrolo[3,4-b][1,4]oxazinyl,
octahydro-1H-pyrrolo[3,4-c]pyridinyl,
2,3-dihydrobenzofuran-2-yl, 2,3-dihydrobenzofuran-3-yl, indolin-l-yl, indolin-
2-yl, indolin
3-yl, 2,3-dihydrobenzothien-2-yl, octahydro-1H-indolyl, and
octahydrobenzofuranyl.
[0182]
The spiro-heterocyclyl may be 7-11 membered spiro-heterocyclyl, and preferably
7-11 membered saturated spiro-heterocyclyl; examples of which include, but are
not limited to:
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
KHN NH HN 0 FIN NH CJ N NH
NH
H , HN NH
OCNI)TH
fiNly> oCH HNLDO HN
N
H , and .
[0183] The bridged heterocyclyl may be 7-11 membered bridged
heterocyclyl, and
preferably 7-11 membered saturated bridged heterocyclyl; examples of which
include, but are
H
N
HNO C HNC Th\T
not limited to: D\TH NH
Gm) HN\ ._ h NH
,
, and \----' .
[0184] The "pharmaceutically acceptable salt" described herein refers
to both
pharmaceutically acceptable acid and base addition salts and solvates. Such
pharmaceutically
acceptable salts include salts of the following acids: hydrochloric acid,
phosphoric acid,
hydrobromic acid, sulfuric acid, sulfurous acid, formic acid, toluenesulfonic
acid,
methanesulfonic acid, nitric acid, benzoic acid, citric acid, tartaric acid,
maleic acid, hydroiodic
acid, alkanoic acid (such as acetic acid, HOOC-(CH2)n-COOH (wherein n is 0-
4)), and the like.
Such pharmaceutically acceptable salts further include salts of the following
bases: sodium,
potassium, calcium, ammonium, and the like. Those skilled in the art know a
variety of
pharmaceutically acceptable non-toxic addition salts.
[0185] All numerical ranges described herein include both endpoints of
the ranges, all
integers within the range and subranges formed by these integers. For example,
"5-11
membered" includes 5, 6, 7, 8, 9, 10 or 11 membered, "5-6 membered" includes 5
or 6
membered, and "7-11 membered" includes 7, 8, 9, 10 or 11 membered and so on.
[0186] The "one to more" as described herein with respect to a substituent
refers to the
number of substituents with which all positions can be chemically substituted
in the substituted
41
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
group, preferably 1 to 6, more preferably 1 to 5, more preferably 1 to 3, and
more preferably 1 to
2.
[0187] The "crystal form" described herein may be prepared from the
compound of
general formula (I) by conventional methods for preparing crystal forms used
in the art.
[0188] The "stereoisomer" of the compound of general formula (I) described
herein
means that an enantiomer can be formed when asymmetric carbon atoms are
present in the
compound of general formula (I); a cis-trans isomer can be formed when a
carbon-carbon
double bond or a ring structure is present in the compound; a tautomer can be
formed when a
ketone or oxime is present in the compound. All enantiomers, diastereomers,
racemates,
cis-trans isomers, tautomers, geometric isomers and epimers of the compound of
general
formula (I) as well as mixtures thereof are included in the scope of the
present invention.
[0189] The preparation of the compound of general formula (I)
described herein can be
found in the detailed description of W02018108079A1.
[0190] The "therapeutically effective amount" described herein refers
to an amount of the
aforementioned compound or the pharmaceutically acceptable salt, the
stereoisomer and the
crystal form thereof and/or the pharmaceutical formulation that, when
administered to a patient,
is at least capable of alleviating symptoms of the patient's condition. An
actual amount
comprising the "therapeutically effective amount" will vary depending on a
variety of
circumstances, including, but not limited to, the particular condition being
treated, the severity
of the condition, the physique and health of the patient, and the route of
administration. The
appropriate amount can be readily determined by skilled medical practitioners
using methods
known in the medical field.
[0191] The "mammal" described herein refers to a group of animals of
the class
mammalia of the subphylum vertebrates, which are lactated by the mammary
glands to suckle
.. young children. It can be divided into human mammals and non-human mammals.
Examples of
non-human mammals include, but are not limited to, tigers, leopards, wolves,
deer, giraffes,
minks, monkeys, orangutans, tapirs, foxes, sloths, bears, koala bears, polar
bears, elephants,
musk-oxen, rhinoceros, sea cattle, lions, red pandas, pandas, warthogs,
antelopes, koalas,
42
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
lynxes, pangolins, anteaters, otters, dolphins, walruses, seals, whales,
platypuses, hedgehogs,
kangaroos, hippopotamus, weasels, badgers, leopard cats , horses, cattle,
sheep, mules,
donkeys, dogs, mice, cats, and rabbits.
[0192] The "pharmaceutically acceptable carrier" described herein
includes, but is not
limited to, solid carriers and liquid carriers. Suitable solid carriers
include, but are not limited
to, cellulose, glucose, lactose, mannitol, magnesium stearate, magnesium
carbonate, sodium
carbonate, sodium saccharin, sucrose, dextrin, talc, starch, pectin, gelatin,
tragacanth, arabic
gum, sodium alginate, p-hydroxylbenzoate, methylcellulose, sodium
carboxymethyl cellulose,
low-melting wax, cocoa butter, and the like. Suitable liquid carriers include,
but are not limited
to, water, ethanol, polyol (such as glycerin, propylene glycol and liquid
polyethylene glycol),
vegetable oil, glyceride and mixtures thereof.
[0193] The "FGFR inhibitor" described herein is a small-molecule
inhibitor drug which
is available on the market or is in clinical research or preclinical research
and is proved to be
capable of targeting FGFR kinase to play a role in treating cancer, and in
particular to a drug for
treating cholangiocarcinoma, such as: Erdafitinib, BGJ-398, TAS-120 and INCB-
054828.
BENEFICIAL EFFECTS OF PRESENT INVENTION
[0194] The compound of general formula (I) or a pharmaceutically
acceptable salt, a
stereoisomer and a crystal form thereof can effectively treat biliary tract
cancer, and particularly
has a remarkable treatment effect on cholangiocarcinoma. Researches show that
the compound
has a good treatment effect on cholangiocarcinoma with non-FGFR aberration,
cholangiocarcinoma with FGFR aberration, various FGFR drug-resistant
cholangiocarcinomas
and cholangiocarcinoma of various anatomical sites.
DETAILED DESCRIPTION
[0195] In order to make the objective, technical solutions and
advantages of the present
invention more apparent, the present invention is further described in detail
below. It should be
apparent that the examples described herein are only some examples of the
present invention,
but not all examples. Based on the examples of the present invention, all
other examples
43
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
obtained by those of ordinary skill in the art without creative work shall
fall within the
protection scope of the present invention.
[0196] The abbreviations and English expressions used in the present
invention have the
following meanings:
Table 2. Abbreviations and English expressions
Abbreviation/English Meaning
DMSO Dimethyl sulfoxide
MOPS 3-morpholinopropanesulfonic acid
EDTA Ethylenediaminetetraacetic acid
MnC12 Manganese chloride
MC Methylcellulose
ATP Adenosine triphosphate
Glu Glutamic acid
Tyr Tyrosine
PEG Polyethylene glycol
Qd Administration once daily
Qw Administration once a week
BiW Administration twice a week
[0197] Experimental Example 1: Assay on Inhibitory Activity of
Compounds of the
Present Invention Against FGFR Wild-Type Enzyme
[0198] Test samples: the compounds of the present invention, which
have structures
shown in Table 1 and are prepared as described in the embodiments of
W02018108079A1.
[0199] Experiment method
[0200] (1) Preparation of the compound plate
[0201] The compounds were each dissolved in DMSO to prepare stock
solutions with a
maximum concentration of 500 M. The compound stock solutions were diluted
with DMSO to
final concentrations of 500, 150, 50, 15, 5, 1.5, 0.5, 0.15, 0.05 !LIM to
obtain compound working
solutions (50 x).
44
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0202] (2) Experimental procedures
[0203] a) Preparation of different reaction systems
[0204] FGFR1(h) was dissolved in 8 mM MOPS (pH 7.0), 0.2 mM EDTA and
250 !LIM
KKK SPGEYVNIEF G;
[0205] FGFR2(h) was dissolved in 8 mM MOPS (pH 7.0), 0.2 mM EDTA, 2.5 mM
MnC12 and 0.1 mg/mL poly (Glu, Tyr) (4:1);
[0206] FGFR3(h) was dissolved in 8 mM MOPS (pH 7.0), 0.2 mM EDTA, 10
mM
MnC12 and 0.1 mg/mL poly (Glu, Tyr) (4: 1);
[0207] b) Enzymatic reaction
[0208] The reaction was initiated by the addition of 10 mM magnesium
acetate and 10
!LIM [y-3311-ATP. After incubation at room temperature for 40 min, the
reaction was stopped by
using a 3% (v/v) phosphoric acid solution. 10 [IL of the reaction solution was
pipetted onto P30
filter paper, washed 3 times with 75 mM phosphoric acid solution for 5 min
each time, dried
and counted by scintillation. 2% (v/v) DMSO was taken as a positive control
(Max) instead of
the compound solutions; high concentration positive control inhibitor (10 laM
Staurosporine)
was taken as a negative control (Min) instead of the compound solutions.
[0209] Test results:
Table 3. Inhibitory activity of compounds of the present invention against
wild-type FGFRs
(IC5o)
FGFR1 FGFR2 FGFR3
Test samples (nM) (nM) (nM)
Compound 29 2 3 5
[0210] It can be seen from the experimental results in Table 3 that the
compounds of the
present invention can target FGFR1-3, have a good inhibitory activity against
FGFR1-3, and
have good clinical application potential in the aspect of treating diseases
mediated by FGFR1-
3.
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0211] Experimental Example 2: Assay on Inhibitory Activity of
Compounds of the
Present Invention Against Wild-Type and Mutant FGFR
[0212] Test samples: the compounds of the present invention, which
have structures
shown in Table 1 and are prepared as described in the embodiments of
W02018108079A1.
Table 4. Names and sources of enzymes/reagents
Abbreviations Name Source
FGFR2 WT Wild-type FGFR2 enzyme Invitrogen
FGFR2 N549H N549H gene mutant FGFR2 enzyme Signalchem
FGFR2 V564F V564F gene mutant FGFR2 enzyme Signalchem
FGFR3 WT Wild-type FGFR3 enzyme Invitrogen
FGFR3 K650E K650E gene mutant FGFR3 enzyme Signalchem
Homogeneous time-resolved fluorescence Cisb .
HTRF KinEASE-TK kit io
method kit
BIBF 1120 Nintedanib ChemExpress
[0213] Experiment method
[0214] (1) Preparation of the compound plate
[0215] The compounds were dissolved in DMSO and 3-fold diluted with
DMSO to
obtain 10 serially diluted stock solutions. The stock solutions were added
into a 384-well plate
to obtain a 3-fold diluted series of 10 concentrations of the compound
starting from 101uM.
[0216] (2) Experimental procedures
[0217] Different enzyme solutions (2x) were prepared, transferred into
the 384-well
plate, incubated with the compound solutions with different concentrations for
10 min at room
temperature, and a mixed solution (2x) of biotinylated tyrosine kinase
substrate/ATP was added
to activate the reaction. After incubation for 50 min at room temperature, an
HTRF detection
reagent and a corresponding kinase antibody cryptate were added, and after
incubation for 1 h at
room temperature, fluorescence readings at 615 nm (cryptate) and 665 nm (HTRF
detection
reagent) were detected by using an Envision 2104 multifunctional microplate
reader. 10 IuM
BIBF-1120 was taken as a compound positive control (PC) instead of the
compound solutions,
46
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
and 0.1% (v/v) DMSO was taken as a solvent negative control (VC) instead of
the compound
solutions.
[0218] (3) Data processing
[0219] The fluorescence ratio of 665/615 nm was calculated, and the
enzyme activity
inhibition rate (%) was calculated according to the following formula:
Fluorescence ratio of compounds ¨ Mean
fluorescence ratio of PC
Inhibition rate % = 100 ____________________________________________ x 100
Mean fluorescence ratio of VC ¨ Mean fluorescence
ratio of PC
[0220] IC50 values were fitted using GraphPad 6.0 based on inhibition
rates of
compounds with different concentrations.
[0221] Test results:
Table 5. Inhibitory Activity of Compounds of the Present Invention Against
FGFR enzyme
(IC5o)
Test samples Enzymes IC50 (nM)
FGFR2 WT 0.5
Compound 29 FGFR2 N549H 1.9
FGFR2 V564F 0.7
FGFR3 WT 1.0
Compound 29
FGFR3 K650E 1.7
[0222] It can be seen from the experimental results in Table 5 that
the compounds of the
present invention have an obvious inhibitory effect on both wild-type and
mutant FGFR2 and
FGFR3, which indicates that the compounds of the present invention have better
clinical
application potential in treating diseases mediated by wild-type and/or mutant
FGFR, such as
cholangiocarcinoma.
[0223] Experimental Example 3: Cholangiocarcinoma Organoid Experiment
of
Compounds of the Present Invention
47
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0224] Test samples: the compounds of the present invention, which
have structures
shown in Table 1 and are prepared as described in the embodiments of
W02018108079A1.
[0225] Organoid information: Human distal cholangiocarcinoma (dCC)
from K2
Oncology Co. Ltd., Beijing, code KOBD-002
Table 6. Names and sources of reagents and instruments
Name Source/model No.
96-channel high-throughput full-automatic liquid workstation NAYO N96
Microplate reader BMG FLUOstar
Fetal bovine serum Gibco
Penicillin/streptomycin double-antibody Gibco 15140122
Pancreatin Gibco 12604013
Cell Viability fluorescence detection kit CellTiter-Glog Luminescent Cell
Promega G7573
Viability Assay
K2 Oncology,
GAS-Ad-BD medium
K2O-CML-01801
BEZ235 MCE
Gemcitabine
Cisplatin MCE
5-fluorouracil MCE
Matrigel BD 356231
[0226] Experiment method
[0227] (1) Preparation of the compound plate
[0228] The compounds were dissolved in DMSO, then diluted 3-fold to
obtain stock
solutions (1000 x) with 10-concentration gradients, and diluted 100-fold using
GAS-Ad-BD
medium to obtain working solutions (10 x).
[0229] (2) Experimental procedures
[0230] After tumor organoids could be passaged, matrigel was melted at
4 C for later
use. Cultured tumor organoids were collected using a Pasteur dropper and added
with
pancreatin to form a single cell suspension. After cell counting, the cell
concentration was
adjusted to 8 x 104 cell/mL by using GAS-Ad-BD medium, and 2 mL of the cell
suspension was
48
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
placed on ice for later use. A matrigel mixed solution was prepared by mixing
the cell
suspension and the matrigel and then placed on ice for later use, 50 uL of the
mixed solution
was added to a 96-well plate, incubated at 37 C for 30 min and added with GAS-
Ad-BD
medium, and after 2 days of incubation in a 37 C cell incubator, the
formation and growth of
tumor organoids were observed.
[0231] After the formation and growth of the tumor organoids were
observed, 10 III, of
working solutions (10 x) with 10-concentration gradients prepared on the same
day were
sequentially added. The solutions were incubated at 37 C for 96 h with 5%
carbon dioxide. The
starting concentrations of each compound were as follows: compound 29 at 10
IuM,
gemcitabine at 40 IuM, cisplatin at 60 IuM, and 5-fluorouracil at 30 IuM. A
solvent negative
control group (DMSO, 100% survival) and a positive control group (2.5 M
BEZ235, 0%
survival) were set.
[0232] After the cultivation was completed, 70 [IL of CellTiter-Glo0
solution was added,
and the fluorescence value was determined after the operation was performed
according to the
specification.
[0233] (3) Data processing
[0234] The corresponding compound concentration at 50% survival was
calculated by
using GraphPad Prism 5 software, that is the ICso value (absolute ICso value)
for the compounds
on these cells.
[0235] Test results:
Table 7. Inhibitory Activity of Compounds of the Present Invention Against
KOBD-002
Distal Cholangi oc arcinom a Organoids
Test samples IC50(JtM)
Compound 29 1.27
Gemcitabine 17.97
Cisplatin 18.77
5-fluorouracil >30
49
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0236] It can be seen from the experimental results in Table 7 that
the compounds of the
present invention have a good inhibitory activity against KOBD-002 distal
cholangiocarcinoma
organoids, and are superior to gemcitabine, cisplatin and 5-fluorouracil,
which indicates that the
compounds have good clinical application potential in treating
cholangiocarcinoma, and
especially distal cholangiocarcinoma.
[0237] Experimental Example 4: In Vivo Efficacy Test of Compounds of
the Present
Invention on HuPrime Human Cholangiocarcinoma CC6204 Subcutaneous Xenograft
Tumor Model
[0238] Test samples: the compounds of the present invention, which
have structures
shown in Table 1 and are prepared as described in the embodiments of
W02018108079A1;
gemcitabine hydrochloride, commercially available.
[0239] The source of tumor mass: CC6204 was a HuPrime xenograft model
established
by a female cholangiocarcinoma patient. The pathological diagnosis was
intrahepatic
cholangiocarcinoma, with FGFR2-BICC1 fusion aberration.
[0240] Animals: Balb/c nude female mice at 5-6 weeks (weeks of age at time
of mice
in ocul ati on).
[0241] Test method:
[0242] (1) Construction and grouping of tumor-bearing mice
[0243] Tumor tissues were collected from tumor-bearing mice of HuPrime
cholangiocarcinoma xenograft model CC6204, cut into tumor masses of a diameter
of 2-3 mm
and then subcutaneously inoculated into the right anterior scapula of the
Balb/c nude mice, and
the mice were grouped and administered when an average volume of tumors
reached 133 mm3.
Grouping method: animals were weighed before administration and tumor volumes
were
measured. Grouping was designed in blocks according to the tumor volume, with
6 mice per
group.
[0244] (2) Administration regimen
Table 8. Administration regimen
Date Recue/Date Received 2022-08-23
CA 03172795 2022-08-23
Do sing Route Frequency
Do sage
Administration
Group Vehicle volume of of
(mg/kg) period
(mL/kg) administration administration
h 0.5% (v/v) MC Oral
Veicle
containing 0.5% 0 10 intragastric Qd 68 days
control
(v/v) Tween 80 administration
Oral
Compound 29 0.5%(w/v)MC 15 10 intragastric
Qd 68 days
administration
Gemcitabine
Normal saline 120 10 Intraperitoneal Qw a 68 days
hydrochloride
[0245] Note: a gemcitabine hydrochloride was administered once a week
for a total of 10.
[0246] (3) Experimental observation index
[0247] Animals were monitored daily for health and mortality, body
weight and tumor
volume were measured twice a week, and samples were collected after the last
administration.
The therapeutic effect of tumor volume was evaluated by TGI%, wherein the
relative tumor
inhibition rate TGI (%): TGI = 1¨TIC (%). T/C% is the relative tumor
proliferation rate, i.e., the
percentage of the relative tumor volume in the treatment and control groups at
a given time
point. T and C are relative tumor volumes (RTVs) of the treatment and control
groups at a given
time point, respectively.
[0248] The calculation formula is as follows: TIC % = TRTv / CRTv x 100%
(Twfv: mean
RTV for treatment group; CRTv: mean RTV for vehicle control group; RTV =
Vt/Vo, wherein
Vo is the tumor volume of the animal at the time of grouping, and Vt is the
tumor volume of the
animal after treatment). The drug is considered to be effective according to
the National
Institute of Health (NIH) Guidelines that TGI is > 58%.
[0249] Test results:
Table 9. Effect of Compounds of the Present Invention on Tumor Growth in Mice
of
HuPrime Human Cholangiocarcinoma CC6204 subcutaneous xenograft tumor model
Number of Tumor volume a TGI
Group Pc
animals (mm3) (0/01,
Vehicle control 6 696.52 -- --
Compound 29 6 147.8 80 <0.001
51
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
Gemcitabine
6 397.22 43
0.973
hydrochloride
[0250] Note: a: tumor volumes were statistic data for 21 days of
administration. b: TGI:
relative tumor inhibition rate, statistic data for 21 days of administration.
C: P <0.05 indicates
that there was a statistical difference, P < 0.01 indicates that there was a
significant statistical
difference, and P < 0.001 indicates that there was an extremely significant
statistical difference.
Table 10. Effect of Compounds of the Present Invention on Survival Rate of
Mice of
HuPrime Human Cholangiocarcinoma CC6204 subcutaneous xenograft tumor model
Number of Number of surviving
Group Survival rate (%) pb
animals animals a
Vehicle control 6 0 0 --
Compound 29 6 6 100
<0.001
Gemcitabine
6 1 16.7 0 A67
hydrochloride
[0251] Note: a: surviving animals were data statistics after the last
administration (day
67). b: P <0.05 indicates that there was a statistical difference, P < 0.01
indicates that there was
a significant statistical difference, and P < 0.001 indicates that there was
an extremely
significant statistical difference.
[0252] It can be seen from the experimental results in Table 9 and
Table 10 that the
compounds of the present invention have a remarkable inhibitory effect on
HuPrime human
cholangiocarcinoma CC6204 subcutaneous xenograft tumor model, effectively
prolong the life
cycle of tumor-bearing animals, and are significantly superior to clinical
standard treatment of
gemcitabine, which indicates that the compounds of the present invention can
be used in
clinical treatment of intrahepatic cholangiocarcinoma tumors with FGFR2
aberration, and have
good clinical application potential.
[0253] Experimental Example 5: In Vivo Efficacy Test of Compounds of
the Present
Invention on HuPrime Human Cholangiocarcinoma CC6639 Subcutaneous Xenograft
Tumor Model
[0254] Test samples: the compounds of the present invention, which
have structures
shown in Table 1 and are prepared as described in the embodiments of
W02018108079A1.
52
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0255] The source of tumor mass: CC6639 was a HuPrime0 xenograft model
established
by a male cholangiocarcinoma patient. The pathological diagnosis was
intrahepatic
cholangiocarcinoma, with no FGFR2 aberration.
[0256] Animals: Balb/c nude female mice at 4-5 weeks (weeks of age at
time of mice
in ocul ati on).
[0257] Experiment method
[0258] (1) Construction and grouping of tumor-bearing mice
[0259] Tumor tissues were collected from tumor-bearing mice of HuPrime
cholangiocarcinoma xenograft model CC6639, cut into tumor masses of a diameter
of 2-3 mm
and then subcutaneously inoculated into the right anterior scapula of the
Balb/c nude mice, and
the mice were grouped and administered when an average volume of tumors
reached 202mm3.
Grouping method: animals were weighed before administration and tumor volumes
were
measured. Grouping was designed in blocks according to the tumor volume, with
5 mice per
group.
[0260] (2) Administration regimen shown in Table 11
Table 11. Administration regimen
Do sing
Do sage Route of Frequency of
Administration
Group Vehicle volume
i
(mg/kg)
(mL/kg) administration adm nistration
period
Vehicle 0.5% Oral intragastric
0 10 Qd 21
days
control (w/v)MC administration
Compound 0.5% Oral intragastric
15 10 Qd 21
days
29 (w/v)MC administration
[0261] (3) Experimental observation index
[0262] Animals were monitored daily for health and mortality, body
weight and tumor
volume were measured twice a week, and samples were collected after the last
administration.
The therapeutic effect of tumor volume was evaluated by TGI%, wherein the
relative tumor
inhibition rate TGI (%): TGI = 1¨TIC (%). T/C% is the relative tumor
proliferation rate, i.e., the
percentage of the relative tumor volume in the treatment and control groups at
a given time
53
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
point. T and C are relative tumor volumes (RTVs) of the treatment and control
groups at a given
time point, respectively. The calculation formula is as follows: TIC % = Twry
/ CRry x 100%
(TRrv: mean RTV for treatment group; CRrv: mean RTV for vehicle control group;
RTV =
Vt/Vo, wherein Vo is the tumor volume of the animal at the time of grouping,
and Vt is the tumor
volume of the animal after treatment). The drug is considered to be effective
according to the
NTH Guidelines that TGI is > 58%.
[0263] Test results:
Table 12. Effect of Compound 29 of the present invention on tumor growth in
mice of
HuPrime human cholangiocarcinoma CC6639 subcutaneous xenograft tumor model
Tumor volume TGI
Group Number of animals pb
(mm) (0/0)a
Vehicle control 5 2195.88 -- --
Compound 29 5 623.72 72 0.0045
[0264] Note: a: statistical data after the last administration; TGI:
relative tumor inhibition
rate. b: P <0.05 indicates that there was a statistical difference, P <0.01
indicates that there was
a significant statistical difference, and P < 0.001 indicates that there was
an extremely
significant statistical difference.
[0265] It can be seen from the experimental results in Table 12 that
Compound 29 has a
remarkable inhibitory effect on HuPrime human cholangiocarcinoma CC6639
subcutaneous
xenograft tumor model, which indicates that the compound can be used in
clinical treatment of
intrahepatic cholangiocarcinoma tumors with non-FGFR2 aberration and has good
clinical
application potential.
[0266] Experimental Example 6: In Vivo Efficacy Test of Compounds of
the Present
Invention on Human Perihilar Cholangiocarcinoma PDTX Subcutaneous Xenograft
Tumor Model
[0267] Test samples: the compounds of the present invention, which
have structures
shown in Table 1 and are prepared as described in the embodiments of
W02018108079A1.
54
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
[0268] The source of tumor mass: the human perihilar
cholangiocarcinoma tumor sample
was derived from a female patient.
[0269] Animals: NCG male mice at 5-8 weeks.
[0270] Test method:
[0271] (1) Construction and grouping of tumor-bearing mice
[0272] The tumor samples excised in the surgery were inoculated into
mice as PO
generation and then passaged as P1 generation for drug efficacy evaluation.
The tumor masses
were inoculated into the right back of the mice, and the mice were grouped and
administered
when an average volume of tumors reached approximately 100 mm3. Grouping
method:
animals were weighed before administration and tumor volumes were measured.
Grouping was
designed in blocks according to the tumor volume, with 6 mice per group.
[0273] (2) Administration according to administration regimen of Table
13
Table 13. Administration regimen
Do sing
Do sage Route of Frequency of
Administration
Group Vehicle volume
(mg/kg)
(mL/kg) administration administration period
Vehicle control 0.5%(w/v)MC 0 10 Oral intragastric Qd 25
days
administration
Oral intragastric
Compound 29 0.5%(w/v)MC 15 10 Qd 25 days
administration
Gemcitabine
30 10 BiW
hydrochloride Nonnal saline +3 +10 Intraperitoneal Qw 25 days
+ Cisplatin
[0274] (3) Experimental observation index
[0275] Animals were monitored daily for health and mortality, body weight
and tumor
volume were measured twice a week, and samples were collected after the last
administration.
The therapeutic effect of tumor volume was evaluated by TGI%, wherein the
relative tumor
inhibition rate TGI (%): TGI = 1¨T/C (%). T/C% is the relative tumor
proliferation rate, i.e., the
percentage of the relative tumor volume in the treatment and control groups at
a given time
point. T and C are relative tumor volumes (RTVs) of the treatment and control
groups at a given
Date Regue/Date Received 2022-08-23
CA 03172795 2022-08-23
time point, respectively. The calculation formula is as follows: TIC % = TRTv
/ CRTv x 100%
(TRTv: mean RTV for treatment group; CRTv: mean RTV for vehicle control group;
RTV =
Vt/Vo, wherein Vo is the tumor volume of the animal at the time of grouping,
and Vt is the tumor
volume of the animal after treatment). The drug is considered to be effective
according to the
NIH Guidelines that TGI is > 58%.
[0276] Test results:
Table 14. Effect of Compound 29 of the Present Invention on Tumor Growth in
Mice of
HuPrime Human Cholangiocarcinoma CC6204 subcutaneous xenograft tumor model
Number of Tumor volume a TGI
Group Pc
animals (mm) ((yob
Vehicle control 6 233.9 -- --
Compound 29 6 70.9 70 0.0039
Gemcitabine hydrochloride
6 157.3 35 0.247
+ Cisplatin
[0277] Note: a: tumor volumes were statistical data for 21 days of
administration; b: TGI:
.. relative tumor inhibition rate, statistic data for 21 days of
administration. C: P <0.05 indicates
that there was a statistical difference, P < 0.01 indicates that there was a
significant statistical
difference, and P < 0.001 indicates that there was an extremely significant
statistical difference.
[0278] It can be seen from the experimental results in Table 14 that
Compound 29 has a
remarkable inhibitory effect on human perihilar cholangiocarcinoma PDTX
subcutaneous
xenograft tumor model, and is significantly superior to the clinical standard
treatment of
gemcitabine + cisplatin, which indicates that the compound of the present
invention can be used
in clinical treatment of perihilar cholangiocarcinoma tumors and has good
clinical application
potential.
[0279] The above description is only for the purpose of illustrating
the preferred example
of the present invention, and is not intended to limit the scope of the
present invention. Any
modifications, equivalents, improvements and the like made without departing
from the spirit
and principle of the present invention should be included in the protection
scope of the present
invention.
56
Date Regue/Date Received 2022-08-23
